KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Average (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Equity Average data on record, last reported at $20.7 million in Q4 2025.

  • For Q4 2025, Equity Average fell 95.68% year-over-year to $20.7 million; the TTM value through Dec 2025 reached $20.7 million, down 95.68%, while the annual FY2025 figure was $256.0 million, 57.62% down from the prior year.
  • Equity Average reached $20.7 million in Q4 2025 per PACB's latest filing, down from $48.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $815.9 million in Q4 2021 and bottomed at $20.7 million in Q4 2025.
  • Average Equity Average over 5 years is $501.8 million, with a median of $582.8 million recorded in 2022.
  • Peak YoY movement for Equity Average: soared 543.14% in 2021, then tumbled 95.68% in 2025.
  • A 5-year view of Equity Average shows it stood at $815.9 million in 2021, then fell by 27.11% to $594.7 million in 2022, then increased by 23.17% to $732.5 million in 2023, then tumbled by 34.49% to $479.9 million in 2024, then crashed by 95.68% to $20.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $20.7 million in Q4 2025, $48.8 million in Q3 2025, and $76.6 million in Q2 2025.